Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013 | Director | November 05, 2025 | November 07, 2025 |
| DAVITA INC.DVA · Entity 3482 | CFO and Treasurer | May 07, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHAMPIONS ONCOLOGY, INC.
Report date November 05, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2035-11-05 | Direct | 21,216 |
Reported balance
After 2025-11-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-05 · Grant · Acquired 21,216 · Balance 21,216 F1: The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.
DAVITA INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,434 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Sale · Disposed 51,471 · Balance 132,434 F1: Represents the weighted average sale price of $192.099. The range of prices for the sale of these shares was $191.510 - $192.765 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sale price of $192.099. The range of prices for the sale of these shares was $191.510 - $192.765 rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KINDRED HEALTHCARE, INC
Report date July 02, 2018 · Filed July 02, 2018
Section 16 reporting ended · disclosed 2018-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 1
1 source rowRow 1 · 2018-07-02 · Disposition to issuer · Disposed 75,167 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 94,405 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 7 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,405 Underlying: Common Stock · 94,405 shares Expires 2025-11-01 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F5 · derivative.exercise_date: Vested as to 70,804 shares on grant; remainder to vest on October 31, 2016. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 88,470 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 6 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,470 Underlying: Common Stock · 88,470 shares Expires 2024-11-01 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: Fully vested upon grant. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 14,552 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 5 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,552 Underlying: Common Stock · 14,552 shares Expires 2023-11-05 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: Fully vested upon grant. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 101,521 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 4 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,521 Underlying: Common Stock · 101,521 shares Expires 2023-11-05 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F4 · derivative.exercise_date: Vesting to occur upon completion of performance criteria that have not been set. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 101,521 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 3 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,521 Underlying: Common Stock · 101,521 shares Expires 2023-11-05 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F3 · derivative.exercise_date: Vested as to 74,529 shares on grant; remainder to vest on November 5, 2016. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 150,795 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 2 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,795 Underlying: Common Stock · 150,795 shares Expires 2025-10-25 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: Fully vested upon grant. Read SEC document |
| July 21, 2016 Filed Sep 14, 2016 20:03 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 150,795 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001628280-16-019572 · wf-form4_147388339023554.xml · derivative · entry 1 ACKERMAN JOEL · CIK 0001220630 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,795 Underlying: Common Stock · 150,795 shares Expires 2025-10-25 F2 · price: The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price. F1 · derivative.exercise_date: Fully vested upon grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.